Compare Illinois Tool Works Inc. (ITW) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Illinois Tool Works Inc. vs Travere Therapeutics Inc. Common Stock — how do they compare? Illinois Tool Works Inc. trades at $269.47 (market cap $75.85B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B). The key difference: Illinois Tool Works Inc. is far larger — about 15.5× Travere Therapeutics Inc. Common Stock's market cap, and Illinois Tool Works Inc. pays a 2.58% dividend while Travere Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Illinois Tool Works Inc. for 66 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| ITW | TVTX | |
|---|---|---|
Market Cap | $75.85B | $4.88B |
Volume | 960,368 | 1,668,577 |
Sector | Industrials | Health |
52-Week High | $299.60 | $67.52 |
52-Week Low | $241.07 | $26.79 |
Typical Hold Time | 66 Days | 0 Days |
Enterprise Value | $84.70B | $5.01B |
Dividend Yield | 2.58% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ITW trades at $269.47, up 1.64% with consistent earnings beats in recent quarters. The stock shows bearish technical signals but maintains strong fundamentals with 19.39% net margins and 104.65% ROE. Recent dividend increase to $1.72 reinforces its Dividend King status with 59 years of growth. Revenue stability around $16B and operational cash flow exceeding $3B demonstrate business resilience despite mixed analyst sentiment.
Outlook remains balanced with upside to $276.86 consensus target but faces headwinds from elevated P/E of 24.12 and bearish technical momentum. The company's disciplined capital allocation and sector diversification provide stability, though automotive and foodservice weaknesses present near-term challenges. Valuation appears full given current growth rates.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Illinois Tool Works Inc.
Illinois Tool Works is a diversified global manufacturer that produces specialized industrial equipment, consumables, and related services. The firm operates 87 global divisions through seven distinct operating segments: automotive OEM, construction products, food equipment, specialty products, test/measurement and electronics, polymers and fluids, and welding. About half of its revenue comes from its operations in North America, with the remainder originating from international markets. ITW takes a bottom-up and decentralized approach to portfolio management, with the exception that each segment must apply its 80/20 operating process modeled on the Pareto principle.
Read more on ITW →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
